SCHEMBL12876288

SCHEMBL12876288

CCOC(=O)c1cnn(Cc2nc(-c3cc(C)cc(C#Cc4cccc(C(C)=O)c4)c3)cs2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.37
ACACB O00763 1/20 0.36
GRM5 P41594 5/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
GAA P10253 3/20 0.36
AKT1 P31749 1/20 0.36
CNKSR1 Q969H4 1/20 0.36
GRM2 Q14416 1/20 0.36
JMJD6 Q6NYC1 1/20 0.34
MAPT P10636 4/20 0.34
KDM4E B2RXH2 3/20 0.34
HPGD P15428 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
ALK Q9UM73 1/20 0.34
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876290 0.91 MAPK1 (0.38) MAPK1GRM5L3MBTL1GAAAKT1
SCHEMBL2856251 0.90 GRM5 (0.45) MAPK1GRM5L3MBTL1GAAGRM2
SCHEMBL12876124 0.88 GRM5 (0.47) MAPK1GRM5L3MBTL1GAAAKT1
SCHEMBL1199071 0.87 GAA (0.43) MAPK1L3MBTL1GAAAKT1CNKSR1
SCHEMBL12876280 0.85 GRM2 (0.36) MAPK1GRM5L3MBTL1GAAAKT1
SCHEMBL12876298 0.85 MAPK1 (0.36) MAPK1GRM5L3MBTL1GAAAKT1
SCHEMBL12876283 0.84 GRM2 (0.38) MAPK1L3MBTL1GAAAKT1CNKSR1
SCHEMBL12875915 0.84 MAPK1 (0.44) MAPK1GRM5L3MBTL1GAAAKT1
SCHEMBL12875680 0.82 L3MBTL1 (0.44) MAPK1L3MBTL1GAAAKT1CNKSR1
SCHEMBL1198832 0.81 ALK (0.42) MAPK1GRM5L3MBTL1GAAGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MAPK1 255/4885ACACB 2653/4885GRM5 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.